Equillium Announces Positive Interim Data of Itolizumab in the First-line Treatment of Acute Graft-Versus-Host Disease

NEXT STORY
SCYNEXIS Reports Third Quarter 2020 Financial Results and Provides Company Update
PREV STORY
Atreca to Present at Upcoming Virtual Investor Conferences
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Emergent BioSolutions’ Emergard Auto-Injector Platform for Nerve Agent Antidote Delivery Selected by U.S. Department of Defense and Battelle for Testing and Development

GAITHERSBURG, Md., Feb. 17, 2016 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced ...

author_avatar
NASDAQ Market News

FIT Biotech Oy: FIT Biotech’s Annual Report 2016 published

FIT Biotech Oy Company announcement March 17, 2017 at 12:10 EET FIT Biotech's Annual ...

author_avatar
NASDAQ Market News

Favorable Results from a Multi-Center Analysis of Delcath PHP Therapy to be Published in Journal of Surgical Oncology

NEW YORK, Dec. 05, 2017 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB:DCTH), an interventional ...

author_avatar
NASDAQ Market News